8:30 am Chair’s Opening Remarks
8:45 am Reserved for Expertise Partner
9:00 am Panel Discussion Reserved for Expertise Partner
9:30 am Cannabis 3.0 – Pharmaceutical or Botanical?
Synopsis
- Understand how the marijuana plant has been used as a complex botanical medicine for millennia
- Examine Emyria’s large real-world clinical e-registry and how it provides longitudinal efficacy and safety data on GMP plant-derived oral cannabinoids informing clinical indications and dosing
- Explore Emyria’s development of consistent, stable, highly bioavailable, pure quality, bioidentical cannabinoids for specific indications for pharmaceutical registration
10:00 am Morning Break & Speed Networking
Discovering the Next Generation of Novel Cannabinoid Pharmaceuticals
Chairman: Brian Murphy, Former Chief Executive Officer, Emerald Biosciences
11:00 am Utilizing Rigorous Chemistry Principles to Gain a Clear View of the Potential of THC & CBD
Synopsis
- What are the vital toxicological and PD/PK unknowns that are inhibiting true progress in CDPs?
- How can we go about filling in the gaps as an entire field?
11:30 am AI/ML-Accelerated Plant-Based Drug Discovery
Synopsis
- Discover and evaluate plant-inspired therapeutic mixtures using in-silico tools (artificial intelligence/ machine learning/data analytics)
- Case Study: Examine immune system modulating mixtures designed to treat Cytokine Release Syndrome
- Explore preclinical validation of in-silico drug candidates for Cytokine Release Syndrome (CRS)
Meeting the Growing Need for High-Quality Pure Cannabinoids & Managing Logistical Challenges
Chairman: Mike Woudenberg, Senior Vice President, Chemistry, Manufacturing & Controls, InMed Pharmaceuticals
11:00 am Advances in Biosynthetic Cannabinoid Production of Rare Cannabinoids
Synopsis
- Get an end-to-end view of how Inmed select a cannabinoid to pursue and the process that follows
- Discuss the upcoming cannabinoids the Inmed/ Baymedica team are looking to pursue
11:30 am Biosynthesis of Cannabinoids
Synopsis
- Discuss the creation, characterization, and stress-testing of a robust cannabidiol nanoemulsion created using GRAS (generally recognized as safe) ingredients
- Examine how in a follow-up study, the energy-intensive homogenization step associated with nanoemulsion formation, which requires a specialized instrument leading to higher cost, will be replaced by a solventassisted homogenization protocol, producing a stable emulsion that can then be freeze-dried or spray-dried to form water-redispersible powder formulations
- Explore the design, synthesis, and nanoformulationrelated applications of novel polyphenol-protein conjugate emulsifiers with intrinsic antioxidant properties
12:00 pm Lunch Break
Preclinical Development
Preclinical Development
1:00 pm Challenges & Successes in Moving Promising Preclinical Cannabinoid Drug Candidates to the Clinic
Synopsis
- Identify robust pre-clinical drug targets for cannabinoid drug development
- Evaluate pre- and post-COVID cannabinoid drug development challenges: spotlight on systemic inflammatory disease
- Examine future development of cannabinoid drug products for expanded disease indications
1:30 pm Effective Early Stage Research
Synopsis
- Conducting preliminary preclinical development
- Designing early phase/proof of concept clinical to maximize your chance of achieving success
2:00 pm Pharmaceutical Cannabinoids: A Company Update
Synopsis
- Examine re-purposing of dronabinol for the treatment of obstructive sleep apnea (OSA) and other indications
- Explore completion of two successful Phase 2 clinical trials in OSA
- Develop lipid nanoparticle formulation to overcome current dronabinol limitations
Phytocannabinoid Production
Phytocannabinoid Production
1:00 pm Panel Discussion: Meeting the Growing Demand for Cannabinoids for Research, Therapeutics & Consumer Products
Synopsis
- Identify new learnings that have been discovered in the discussion around phytocannabinoids vs synthetic
- Has the promise of biosynthesis been overestimated?
- Coach before the horse: What is the rationale in trying to explore new cannabinoids when many questions still remain about the therapeutic action of CBD and THC?
1:30 pm SuperFluids™ Manufacturing of Pharmaceutical- Grade Natural Cannabinoids
Synopsis
- Examine core SuperFluids Extraction and chromatographic purification technologies
- Discuss downstream purification and crystallization
- Evaluate chemistry, manufacturing and controls, analytical characterization and cGMP documentation
2:00 pm Building an Ophthalmic Pipeline of Cannabinoid Derivative
Synopsis
- Optimize drug delivery of cannabinoids, starting with occular
- Examine how these learnings can be taken into new therapeutic areas
2:30 pm Afternoon Break
3:00 pm Evolving Federal Cannabis Policy
Synopsis
- Federal lawmakers are introducing bills designing the framework for future legalization, such as the Cannabis Administration and Opportunity Act and State
- Reform Act. Prepare for the potential implications on cannabinoid drug development
- What can we do to further inform lawmakers about the need to incentivize the drug development?
3:30 pm Misconceptions Around the 505(b) Pathway
4:00 pm Updates on UK Medical Cannabis Regulation
Synopsis
- What is understood about the FSA’s recently published list of CBD products?
- How does this impact the wider landscape of medical cannabis and cannabinoid pharmaceutical products?